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S U M M A R Y
Objectives: To describe the clinical and microbiological aspects of high-risk peritonitis and to analyze
their impact on its outcome.
Methods: This was a retrospective review of all culture-positive peritonitis between October 1, 2005 and
September 30, 2009. In accordance with recent Infectious Diseases Society of America (IDSA) guidelines, a
group of high-risk peritonitis patients was selected based on age, severity of illness, underlying diseases,
and acquisition of the infection.
Results: Ninety-three patients with high-risk peritonitis were studied; these patients were divided into
subgroups of those with community-associated disease (14%) and those with healthcare-associated
disease (86%). The median age of patients was 66 (interquartile range (IQR) 22–95) years. The 30-day
mortality rate was 25%. Subgroups differed in age (p = 0.011), degree of comorbidity (p = 0.023), severity
of peritonitis (p = 0.036), admission to the intensive care unit (ICU) (p = 0.002), length of ICU stay
(p < 0.001), length of hospital stay (p < 0.001), cure at day 30 (p = 0.001), and adequate treatment
(p = 0.042). The microbiological etiology and resistance proﬁles were similar between the patient groups.
Adequate empirical treatment was not related to a better outcome. Severity of disease (p = 0.005) and the
presence of enterococci (p = 0.044) were independently associated with mortality.
Conclusions: The mode of acquisition inﬂuences severity and certain parameters of outcome in high-risk
peritonitis, but not its microbiological etiology. The outcome seems to depend primarily on severity of
peritonitis and much less on the adequacy of treatment.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Complicated intra-abdominal infections (cIAI) extend beyond
the hollow viscus of origin into the peritoneal space and are
associated with local or diffuse peritonitis.1 They are an important
cause of morbidity and are frequently associated with a poor
prognosis.2 However, an early clinical diagnosis, followed by
adequate surgery and prompt initiation of appropriate antimicro-
bial therapy can limit the associated mortality.3 A few enteric
species belonging to the normal gut ﬂora are involved in intra-
peritoneal infections.4 Healthcare-associated disease has been
related to the presence of more resistant ﬂora, such as Pseudomo-
nas aeruginosa, Enterobacter spp, enterococci, and Candida spp.5 The
outcome of cIAI depends on several risk factors, such as advanced
age, comorbidity and underlying malignancy, severity of illness,
degree of peritoneal involvement, and presence of a healthcare* Corresponding author. Tel.: +32 2 4773670; fax: +32 2 4772416.
E-mail address: caroline.theunissen@chu-brugmann.be (C. Theunissen).
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doi:10.1016/j.ijid.2011.06.008environment. Recent guidelines issued by the Infectious Diseases
Society of America (IDSA) and the Surgical Infection Society (SIS)
recommend broad-spectrum coverage in the case of high-risk
peritonitis, i.e., healthcare-associated disease or severe communi-
ty-acquired cIAI, because the consequences of treatment failure
may be more signiﬁcant than they are in patients with infections of
mild to moderate severity, although this hypothesis has not been
rigorously examined in clinical trials.6
The aim of our study was to characterize the etiology and
outcome of high-risk peritonitis at our institution, in order to
validate the recent 2010 IDSA guidelines concerning its manage-
ment.
2. Methods
This study was conducted at the Brugmann University Hospital,
an 854-bed (of which 170 are surgical) university hospital in
Brussels, Belgium, with the approval of the institutional review
board. Based on data delivered by the Department of Microbiology,
the medical records of all adult patients with a positive intra-ses. Published by Elsevier Ltd. All rights reserved.
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were reviewed, in order to detect the presence of a cIAI. The
following data were noted: demographic characteristics, underly-
ing disease, administration of antibiotics during the month
preceding the date of onset, clinical presentation, anatomic origin
and severity of peritonitis, admission to the intensive care unit
(ICU), treatment modalities, and outcome at 30 days after the onset
of symptoms. Furthermore, the microbiological etiology of the
infection was determined. Since the appropriate recovery of
anaerobic organisms was not guaranteed during the study period,
we decided to exclude these organisms from the analysis.
2.1. Deﬁnitions
A peritoneal ﬂuid culture was considered positive in the
presence of growth of at least one pathogen. Only peritoneal ﬂuid
drawn by sterile puncture was taken into account.
An intra-abdominal infection was considered complicated if
there was localized or generalized peritonitis as a result of
perforation of stomach, bowel, or biliary tract; intra-abdominal
surgery; or infection of another intra-abdominal organ such as the
liver, spleen, pancreas, or the kidneys. Spontaneous bacterial
peritonitis and peritonitis related to continuous ambulatory
peritoneal dialysis were excluded from the analysis.
High-risk peritonitis was deﬁned as peritonitis requiring broad-
spectrum coverage if the 2010 IDSA guidelines were applied. This
consists of severe community-associated (CA) and healthcare-
associated (HCA) peritonitis. Severe CA peritonitis was deﬁned as
peritonitis acquired in the community associated with at least one
of the following risk factors: higher severity of illness (APACHE II
score 15), advanced age (70 years), and the presence of an
immunocompromised state, deﬁned as the presence of an ongoing
immunosuppressive treatment, radiotherapy, chemotherapy, or
high-dose steroids > 14 days, and/or a history of leukemia,
lymphoma, or AIDS. HCA infection was divided into ‘communi-
ty-onset’ and ‘hospital-onset’ HCA infections. Community-onset
HCA infection involves patients with community-onset peritonitis
and at least one of the following healthcare risk factors: history of
surgery, hospitalization, dialysis, or residence in a long-term care
facility in the 12 months preceding the culture date, the presence
of an invasive device at the time of admission, or a history of
methicillin-resistant Staphylococcus aureus (MRSA) infection or
colonization. Hospital-onset HCA infection involves patients with
positive culture results obtained >48 h after hospital admission.
The severity of underlying disease was measured using the
comorbidity index and score of Charlson et al.7,8 Severity of
peritonitis was assessed by the APACHE II score and the Mannheim
peritonitis index.9,10 Septic shock was deﬁned as sepsis-induced
hypotension despite adequate ﬂuid resuscitation, with hypoperfu-
sion or organ dysfunction.
Empirical antimicrobial therapy was deﬁned as treatment given
within 24 h after diagnosis and/or surgery. It was considered
adequate if active against all the cultured bacteria and/or moulds,
administered intravenously at the correct doses, and given for at
least 7 days, or replaced by an adequate antimicrobial within this
same period.
Outcome was determined at 30 days after the onset of peritonitis.
Patients were considered clinically cured if all infection-related
symptoms and signs had disappeared, without any evidence of a
complication. Infection-related mortality was deﬁned as death
during the cIAI episode, without any other obvious cause.
2.2. Microbiology
Peritoneal ﬂuid was collected in sterile pots or syringes and
transported to the microbiology laboratory by teletube. In theabsence of ﬂuid, a smear of the peritoneal cavity was performed
using an appropriate swab (AMIES, Oxoid Transport System, UK).
Samples were inoculated onto an aerobic medium (blood and
chocolate agar) and incubated at 37 8C (and in 5% CO2 for chocolate
agar plates) for 48 h. Fungi were cultured on Sabouraud–
chloramphenicol plates, incubated at room temperature for 15
days. Microorganisms were mainly identiﬁed using the Vitek 2
System (bioMe´rieux, Marcy l’Etoile, France) or by API (bioMe´rieux)
for streptococci. Susceptibility testing was performed according to
the types of microorganism recovered, and interpretation was
done according to the Clinical and Laboratory Standards Institute
(CLSI) 2005 guidelines.
2.3. Analysis
Continuous variables were tested for normal distribution and
compared using the Student’s t-test or the Mann–Whitney test, as
appropriate. Categorical data were compared using the Chi-square
test or Fisher’s exact test. Continuous variables were expressed as
mean and standard deviation or as median (interquartile range
(IQR)) depending on their distribution. Parameters found to be
different by univariate analysis were entered into a stepwise
logistic regression model with death as the dependant variable. A
double-sided p-value of < 0.05 was considered statistically signif-
icant. Receiver operating characteristic (ROC) curves were used to
obtain cut-off values of mortality-predicting APACHE II score.
3. Results
Analysis of all positive peritoneal ﬂuid cultures between
October 1, 2005 and September 30, 2009 yielded 119 episodes
of cIAI. Ninety-three (78%) of these corresponded to the criteria of
severe CA or HCA peritonitis. Thirteen (14%) had severe CA
peritonitis (group A), because of the presence of: APACHE II score
15 (n = 4), age >70 years (n = 11), and an immunocompromised
state (n = 1); three patients had a combination of two risk factors.
Forty-three patients (46%) had community-onset HCA disease
(group B): history of hospitalization during the last 12 months
(n = 31), residence in a nursing home (n = 7), presence of an
invasive device (n = 3), and history of MRSA infection or coloniza-
tion (n = 2). The remaining 37 patients (40%) had hospital-onset
HCA peritonitis (group C).
The median age of all 93 patients was 66 years (IQR 22–95).
Forty-seven were women and 46 were men. The median Charlson
index was 2 (IQR 0–7) and 26% were immunocompromised. The
anatomic origin of peritonitis was as follows: colon (40%), small
bowel (17%), stomach (13%), biliary tract (8%), appendix (5%), and
other (17%). The median Mannheim peritonitis index was 23 (IQR
8–47) and 61 patients (66%) were admitted to the ICU. An APACHE
II score was available for 57 of the patients and yielded a median
score of 20 (IQR 4–37). The median total hospital stay was 32 days
(IQR 1–291) and the median ICU stay was 12 days (IQR 2–151).
Empiric antibiotic treatment, of which all contained anaerobic
coverage (clavulanic acid, tazobactam, metronidazole, or mer-
openem) was adequate in 68% of the cases (60/88). Antibiotics had
been administered before the onset of cIAI in 25 patients (28%). The
isolated pathogen(s) were resistant to the previously given
antimicrobial in 60% of these episodes. The median time frame
between the onset of infection and surgery was 2 days (IQR 0–60).
Twenty-nine percent needed a second revision after initial surgery
or drainage because of clinical failure, but at day 30, 42% of the
patients were considered cured. The global 30-day mortality rate
was 25%, whereas infection-related mortality amounted to 15%.
Thirty percent of patients admitted to the ICU died.
One hundred and forty-one microorganisms were cultured.
Gram-negative rods were the predominant pathogens (56%),
Table 1
Clinical, treatment, and microbiological characteristics of patients with complicated intra-abdominal infection classiﬁed by mode of acquisition
Characteristic Group A (n = 13)a Group B (n = 43)b Group C (n = 37)c
M/F ratio 5/8 20/23 21/16
Age, years, median (IQR) 78 (64–89) 62 (22–95) 67 (23–88)
Charlson comorbidity index, median (IQR) 1 (0–4) 1 (0–7) 3 (0–7)
Mannheim peritonitis index, median (IQR) 26 (9–39) 21 (10–33) 27 (8–47)
Shock, n (%) 5 (38) 10 (23) 18 (49)
Admission ICU >24 h, n (%) 6 (46) 23 (53) 32 (86)
APACHE II, median (IQR) 26 (10–28) 18 (6–30) 20.5 (4–37)
Length of ICU stay, median (IQR) 18 (2–46) 6 (2–45) 19 (4–188)
Length of hospital stay, median (IQR) 13 (1–61) 21 (2–117) 51 (5–291)
Cure at day 30, n (%) 6 (46) 26 (60) 7 (19)
Death at day 30, n (%) 3 (23) 8 (19) 12 (32)
Antimicrobial treatmentd n = 12 n = 42 n = 34
Narrow-spectrum, n (%) 11 (92) 23 (55) 7 (21)
Broad-spectrum, n (%) 1 (8) 17 (40) 24 (71)
Fluoroquinolone, n (%) 0 3 (7) 3 (9)
Aminoglycoside, n (%) 5 (42) 14 (33) 15 (44)
Adequate treatment, n (%) 9 (75) 33 (79) 18 (53)
Gram-positive bacteria, n (%) 6/18 (33) 16/63 (25) 16/60 (27)
Enterococcus spp, n (%) 2 (33) 6 (37) 12 (75)
Other, n (%) 4 (67) 10 (63) 4 (25)
Enterobacteriaceae, n (%) 10/18 (56) 41/63 (65) 28/60 (47)
Escherichia coli, n (%) 6 (60) 25 (61) 16 (57)
Klebsiella spp, n (%) 1 (10) 7 (17) 6 (21.5)
Other, n (%) 3 (30) 9 (22) 6 (21.5)
Pseudomonas aeruginosa, n (%) 1/18 (6) 2/63 (3) 7/60 (12)
Candida spp, n (%) 1/18 (6) 4/63 (6) 9/60 (15)
Resistance proﬁle Gram-negative rodsd
Narrow-spectrum, n (%) 3 (30) 16 (39) 14 (50)
Broad-spectrum, n (%) 0 10 (24) 12 (43)
Fluoroquinolone, n (%) 0 7 (17) 4 (14)
Aminoglycoside, n (%) 0 8 (20) 2 (7)
M, male; F, female; IQR, interquartile range; ICU, intensive care unit; cIAI, complicated intra-abdominal infection.
a Group A: severe and/or high-risk community-associated cIAI.
b Group B: community-onset healthcare-associated cIAI.
c Group C: hospital-onset healthcare-associated cIAI.
d Narrow-spectrum: amoxicillin–clavulanic acid or cefuroxime; broad-spectrum: third- or fourth-generation cephalosporin, piperacillin–tazobactam or meropenem.
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moulds (10%). Twenty intra-abdominal cultures were positive for
Enterococcus spp, of which eight were Enterococcus faecalis and ﬁve
were Enterococcus faecium, and 35% showed resistance to
ampicillin. S. aureus was found in four cases and none of them
were methicillin-resistant. Escherichia coli was the predominant
Gram-negative (59%), followed by Klebsiella spp (18%) and other
Enterobacteriaceae (ﬁve Proteus spp, four Citrobacter spp, three
Enterobacter spp, three Morganella spp, two Hafnia alvei, and one
Serratia liquefaciens). Thirty-six percent of patients having blood
cultures had associated bacteremia (Gram negative-rods in seven,
Gram-positive cocci in two, a combination of both in two, P.
aeruginosa in one, and anaerobic pathogens in nine).
Clinical, treatment, and microbiological characteristics of
groups A, B, and C are outlined in Table 1. Comparing the three
patient groups yielded differences in age (p = 0.011), Charlson
comorbidity index (p = 0.023), Mannheim peritonitis index
(p = 0.036), admission to the ICU (p = 0.002), length of ICU stay
(p < 0.001), length of hospital stay (p < 0.001), cure at day 30
(p = 0.001), and adequate treatment (p = 0.042). Post-hoc analysis
showed that group A differed from groups B and C in age
(p = 0.014). Group C differed from group B in length of ICU stay
(p < 0.05) and from groups A and B in length of hospital stay
(p < 0.05). No signiﬁcant differences in 30-day mortality or Gram-
negative resistance proﬁle were observed between the patient
subcategories (Table 1).
Table 2 summarizes the univariate analysis of predictors of
death. Patients who died had a higher Charlson index (p = 0.006),
higher Mannheim peritonitis index (p = 0.001), more diffuse
peritonitis (odds ratio (OR) 3.24, 95% conﬁdence interval (CI)1.36–10.74; p = 0.024), more often shock (OR 3.61, 95% CI 1.33–
9.77; p = 0.012), higher APACHE II score (p = 0.001), more often had
the presence of enterococci (OR 3.45, 95% CI 1.20–9.91; p = 0.022),
and more often had empiric treatment >24 h after the onset of
infection (OR 3.64, 95% CI 1.88–11.11; p = 0.026). However, the
survival rate was not inﬂuenced by age, or by the presence of
cancer, acquisition of infection, anatomic origin of peritonitis,
being on antimicrobial therapy at the time of admission,
inadequate treatment, delayed surgery, need for re-intervention,
associated bacteremia, or the presence P. aeruginosa.
Stepwise logistic regression of predictors of death (APACHE II,
diffuse peritonitis, presence of enterococci, and treatment >24 h
after the onset of infection) showed that APACHE II score and the
presence of enterococci were independently related to mortality
(Table 3). ROC curves predicting mortality yielded a cut-off value of
20.5 for APACHE II (area under the curve (AUC) 0.785, 95% CI
0.656–0.914; p = 0.001; sensitivity 81%, speciﬁcity 30%).
4. Discussion
Our study characterized 93 episodes of high-risk peritonitis,
which, if 2010 IDSA guidelines were applied, would have required
broad-spectrum coverage. They were selected among 119 culture-
positive cIAI, implying that the majority (78%) were considered at
risk of developing complications and/or treatment failure. Indeed,
the overall severity of peritonitis was high, demonstrated by the
high median APACHE II score and Mannheim peritonitis index (20
and 23, respectively), admission to the ICU (66%), length of hospital
stay (32 days), subsequent surgical intervention (29%), and
mortality (25%). Community-onset HCA infections showed a less
Table 2
Comparison of clinical, treatment, and microbiological characteristics between non-survivors and survivors
Characteristic Non-survivors (n = 23) Survivors (n = 70) p-Value
Age, years, median (IQR) 72 (50–89) 64 (22–95) NS
Male sex, n (%) 14 (61) 30 (43) NS
Charlson index, median (IQR) 3 (0–6) 1.5 (0–7) 0.006
Cancer, n (%) 8 (35) 14 (20) NS
Acquisition, n (%) NS
Severe and/or high-risk CA 3 (13) 10 (14)
Community-onset HCA 8 (35) 35 (50)
Hospital-onset HCA 12 (52) 25 (36)
Mannheim peritonitis index, median (IQR) 30 (14–39) 21 (8–47) 0.001
Shock, n (%) 13 (57) 20 (29) 0.012
Diffuse peritonitis, n (%) 18 (78) 23 (33) 0.024
APACHE II, median (IQR) 26 (12–37) 19 (4–35) 0.001
Bacteremia, n (%)a 8/17 (47) 13/41 (32) NS
Anatomic origin, n (%) NS
Colon 12 (52) 25 (36)
Small bowel 5 (22) 11 (16)
Stomach 1 (4) 11 (16)
Length of stay, median (IQR) 32 (1–80) 32 (2–291) NS
ICU stay >24 h, n (%) 18 (78) 43 (61) NS
Length of ICU stay, median (IQR) 15 (2–38) 10 (2–151) NS
Adequate empirical treatment, n (%) 14 (61) 46/65 (71) NS
Treatment >24 h after onset of infection, n (%) 5 (22) 31/65 (48) 0.026
Delayed surgery (>24 h), n (%) 8 (35) 37/69 (54) NS
Need for re-intervention, n (%) 6 (26) 21/69 (30) NS
Enterococci, n (%) 9 (39) 11 (16) 0.022
Pseudomonas aeruginosa, n (%) 5 (22) 5 (7) NS
CA, community-associated; HCA, healthcare-associated; ICU, intensive care unit; NS, non-signiﬁcant.
a Blood cultures were carried out for 58 patients.
Table 3
Stepwise logistic regression analysis of predictors of mortality
Parameter Non-survivors (n = 23) Survivors (n = 70) Adjusted odds ratio Conﬁdence interval p-Value
Diffuse peritonitis, n (%) 18 (78) 23 (33) 1.38 0.12–9.05 NS
APACHE II, median (IQR) 26 (12–37) 19 (4–35) 0.87 0.79–0.96 0.005
Treatment delay >24 h, n (%) 5 (23) 30 (51) 0.45 0.095–2.15 NS
Enterococci, n (%) 9 (39) 11 (16) 3.88 1.05–14.28 0.044
NS, non-signiﬁcant.
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illustrated by signiﬁcantly lower lengths of hospital and ICU stays
and less treatment failure at day 30. These ﬁndings suggest that the
clinical course of peritonitis and certain parameters of outcome are
better in non-hospital-onset than in hospital-onset infections.
Hospital-onset peritonitis is known to be characterized by higher
complication and mortality rates, caused by more severe
underlying disease, a delayed diagnosis, and the impaired immune
function in the postoperative period.5,11 A possible explanation lies
in the deﬁnition of community-onset HCA infections, issued by
Klevens et al.12 and used in the 2010 IDSA guidelines. This
deﬁnition is focused on healthcare risk factors for acquiring
invasive MRSA infection; this was associated with greater lengths
of stay, higher mortality, and increased costs, especially in the case
of community-onset HCA infection. It is however less clear
whether MRSA risk factors also apply to cIAI and its outcome.
One of the aims of our study was to focus on the microbiological
etiology of high-risk peritonitis in order to validate (in a
retrospective way) the IDSA recommendation to treat severe CA
or community-onset HCA disease with broad-spectrum antibiotics
such as meropenem, cefepime, piperacillin–tazobactam, etc. Our
data on healthcare-associated disease, even with a community
onset, suggest a rather high Gram-negative resistance rate to
narrow-spectrum antimicrobials such as amoxicillin–clavulanic
acid or cefuroxime (39%), thus suggesting that the healthcare risk
factors of Klevens et al. do apply to the microbiological etiology of
community-onset HCA infections. Severe CA infections were toosmall in number for real conclusions about their microbiology to be
drawn, but the 30% resistance rate of Gram-negative pathogens to
amoxicillin–clavulanic acid or cefuroxime may possibly justify
broad-spectrum coverage.
However, our results showed no correlation between adequacy
of antibiotic treatment and 30-day mortality, despite a reﬁned
deﬁnition by adjusting for mode of administration, dosage, and
duration of antimicrobial therapy. This absence of relationship
between appropriate treatment and outcome might be due to
insufﬁcient study power, because several authors have demon-
strated a higher rate of complications and/or treatment failure in
cases of inadequately treated cIAI, in community- as well as in
healthcare-associated disease.13–15 However, not all of these
studies found differences in mortality.13,16 Possible reasons are
the virulence of the microorganisms and their inoculum size, or
other factors such as host defense and inadequacy of surgical
management explaining failures of antimicrobial therapy even in
the presence of drug-susceptible organisms.4,11,13,16–18 Although
adequacy of treatment did not seem to inﬂuence outcome, we
found that antibiotics given within 24 h after onset of infection was
related to better survival rates in the univariate analysis. Evidence
suggests that antibiotics are most effective during the early phase
of infection because later on, bacterial sequestration in ﬁbrin clots
as well as microbial proliferation limit their action.19
As in patients with non-high-risk peritonitis, clinical course
seemed to depend mostly on severity of peritonitis, measured by
the degree of peritoneal involvement, the APACHE II score, and the
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independently predicted mortality. These scores take into account
not only the severity of peritonitis but also parameters such as
organ failure and underlying illnesses. Our data thus conﬁrm some
of the risk factors for treatment failure mentioned in the IDSA
guidelines.
Only the presence of Enterococcus spp was independently
associated with mortality, in contrast with several studies
demonstrating a relationship between multidrug-resistant
Gram-negative pathogens and mortality.11,14 Severely ill patients
seem to be at risk for enterococcal infections, possibly related to an
immunosuppressed state and prolonged antibacterial exposure.20
A number of limitations are present in our study. First, as it was a
single-center study, microbiological data correspond to our local
ecology and therefore cannot be extrapolated to a larger scale.
Second, only culture-positive peritonitis was taken into account,
thus possibly creating a certain bias by selecting more severe
peritonitis related to a larger microbial burden. Third, the total
number of CA high-risk peritonitis was too small to be of statistical
signiﬁcance, also suggesting that this type of infection is rare and
that there is the risk that it will not be recognized or treated as such.
And ﬁnally, the absence of any relationship between adequacy of
treatment and outcome might be due to insufﬁcient study power.
Despite these limitations, our study shows that the 2010 IDSA
guidelines do apply to cIAI in a European tertiary hospital, in
particular in selecting peritonitis at risk of developing complica-
tions and in predicting their microbiology. However, the clinical
course of high-risk peritonitis and certain parameters of outcome
seem to depend primarily on its severity. Our results also
emphasize the importance of prompt surgery and suggest a
modest impact of adequate antimicrobial treatment, even in high-
risk patients. However, prospective trials are needed to evaluate
the real contribution of antibiotic treatment in this population.
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